New Clinical Trial Data Showed the Addition of INTEGRILIN (Eptifibatide) Injection Achieved Superior Platelet Inhibition and Less Heart Muscle Damage When Compared to a Commonly Used Antiplatelet Regimen Alone

In this article Millennium Pharmaceuticals, Inc. discusses the CLEAR Platelets (Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets) trial, the addition of INTEGRILIN, a potent glycoprotein (GP) IIb-IIIa inhibitor, to a commonly used antiplatelet regimen provided superior platelet inhibition and prevention of heart muscle damage associated with elective coronary stenting in the low-to-moderate risk study patients. Damage to heart muscle has been linked to mortality.

Provided by: Millennium Pharmaceuticals Topic: Software Date Added: Nov 2004 Format: HTML

Find By Topic